Get the tools used by (smart)2 investors.
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Cash from Investing for Nevro Corp

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

NVRO: Nevro Corp

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stim...

5.84 USD
Price
– USD
Fair Value
–
Upside
3.17 - 13.84
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Nevro Corp's Cash from Investing:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-400 M-200 M0 K200 M
Performance Summary
  • Nevro's latest twelve months cash from investing is 14.627 million
  • Nevro's cash from investing for fiscal years ending December 2020 to 2024 averaged -19.288 million.
  • Nevro's operated at median cash from investing of 14.627 million from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Nevro's cash from investing peaked in December 2021 at 201.7 million.
  • Nevro's cash from investing hit its 5-year low in December 2020 of -369.9 million.
  • Nevro's cash from investing decreased in 2020 (-369.9 million, -1,244.0%), 2022 (64.29 million, -68.1%), and 2023 (-7.204 million, -111.2%) and increased in 2021 (201.7 million, -154.5%) and 2024 (14.627 million, -303.0%).

How does Nevro Corp's Cash from Investing benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Nevro Corp because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Nevro Corp Cash from Investing Benchmarks
NameTickerCash from Investing
Boston Scientific CorpNYSE:BSX-5.687 B
Integra LifeSciences HoldingsNASDAQGS:IART-390.8 M
Merit Medical Systems IncNASDAQGS:MMSI-368.7 M
Integer Holdings CorpNYSE:ITGR-195.4 M
Haemonetics CorporationNYSE:HAE-193 M
Teleflex IncorporatedNYSE:TFX-99.358 M
ICU Medical IncNASDAQGS:ICUI-88.96 M
CONMED CorporationNYSE:CNMD-13.084 M
HealthcareSECTOR:HLTH.US-634.736 K
Si-Bone IncNASDAQGM:SIBN12.623 M
Nevro CorpNYSE:NVRO14.627 M
Edwards Lifesciences CorpNYSE:EW2.313 B

Metric Usage: Cash from Investing

Hide this widget
cash_from_investing
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM, YTD
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Cash from Investing in the financials category include:

  • Diluted EPS, Adjusted - This item represents Diluted EPS excluding unusual items.
  • EBIT - Income before interest and taxes adjusted for certain one-time items.
  • Goodwill - This item represents the excess of purchase price paid over the fair market value of net assets acquired, net of any write downs for impairment in value. Goodwill is now no longer amortized over an estimated useful life as was being done earlier (prior to SFAS 142). Instead the balance of goodwill has to be assessed at every reporting period and a write down for impairment has to be recognized when determined. The assessment for impairment is done by applying a fair value based test.
  • As Reported, Operating Income - This item represents the operating income or operating profit as reported by the company in its financial statement.
View Full List

Search for metric or datapoint

Cash from Investing

The total change in cash resulting from a company's investments

Definition of Cash from Investing

Hide this widget

_invpro_glossary_calculation_undefined_year

The tables below summarizes Nevro’s Cash from Investing and common size over the last five years:

Fiscal YearCash from Investing
2020-12-31-369.9 M
2021-12-31201.7 M
2022-12-3164.29 M
2023-12-31-7.204 M
2024-12-3114.627 M

The tables below summarizes Nevro’s Cash from Investing and common size over the last four quarters:

Quarter EndingCash from Investing
2024-03-3125.322 M
2024-06-30-9.528 M
2024-09-30-6.435 M
2024-12-315.268 M
Click the link below to download a spreadsheet with an example Cash from Investing calculation for Nevro Corp below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-60.991 M-35.991 M-10.991 M37.701 M0400800

The chart above depicts the distribution of cash from investing for companies operating in the Healthcare sector in the Developed economic region. Over 3,175 companies were considered in this analysis, and 1,873 had meaningful values. The average cash from investing of companies in the sector is -4.604 M with a standard deviation of 13.113 M.

Nevro Corp's Cash from Investing of 14.627 M ranks in the 96.2% percentile for the sector. The following table provides additional summary stats:

Cash from Investing In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents3,180
Included Constituents1,873
Min-58.641 M
Max35.351 M
Median-504.144 K
Mean-4.604 M
Standard Deviation13.113 M

You can find companies with similar cash from investing using this stock screener.

All rights reserved. Terms Of Use